Head-To-Head Review: Hypertension Diagnostics (OTCMKTS:HDII) and Inovio Pharmaceuticals (NASDAQ:INO)

Hypertension Diagnostics (OTCMKTS:HDII) and Inovio Pharmaceuticals (NASDAQ:INO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Hypertension Diagnostics and Inovio Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hypertension Diagnostics	N/A	N/A	N/A	N/A	N/A
Inovio Pharmaceuticals	$830,000.00	70.12	-$135.12 million	N/A	N/A

Hypertension Diagnostics has higher earnings, but lower revenue than Inovio Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Hypertension Diagnostics and Inovio Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hypertension Diagnostics	0	0	0	0	0.00
Inovio Pharmaceuticals	0	2	3	0	2.60

Inovio Pharmaceuticals has a consensus price target of $12.40, indicating a potential upside of 456.05%. Given Inovio Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Hypertension Diagnostics.

Institutional and Insider Ownership

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 40.0% of Hypertension Diagnostics shares are owned by insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Hypertension Diagnostics and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hypertension Diagnostics	N/A	N/A	N/A
Inovio Pharmaceuticals	N/A	-118.17%	-83.47%

Risk and Volatility

Hypertension Diagnostics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

Summary

Inovio Pharmaceuticals beats Hypertension Diagnostics on 6 of the 9 factors compared between the two stocks.

About Hypertension Diagnostics

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.